Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (71)
Cancellation by sponsor (67)
Australian public assessment report (AusPar) (20)
Prescription medicine registration (20)
Designation or determination (4)
Prescription medicine evaluation (4)
Prescription medicine decision summary (3)

Date

2025 (30)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

189 result(s) found, displaying 81 to 90

LOVAN TAB Fluoxetine (as hydrochloride) 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 August 2022

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
LOVAN fluoxetine 20mg (as hydrochloride) capsule blister pack Cancelled under Section 30(1)(c) of the Act

24 August 2022

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
PROZAC TAB fluoxetine (as hydrochloride) 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
LOVAN LIQUID fluoxetine 20mg/5mL (as hydrochloride) oral liquid bottle Cancelled under Section 30(1)(c) of the Act

24 June 2022

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
VERZENIO (Eli Lilly Australia Pty Ltd)

25 May 2022

Prescription medicine registration

Active ingredients: abemaciclib.
Notice for selpercatinib (Eli Lilly Australia Pty Ltd)

28 March 2022

Designation or determination

Provisional determination
EVIFYNE raloxifene hydrochloride 60mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN R KWIKPEN biosynthetic human neutral insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN NPH KWIKPEN biosynthetic human isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN 30/70 KWIKPEN biosynthetic human 30% neutral 70% isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.